Shares of NeOnc Technologies Holdings jumped 7.1% to $3.75 on August 11, breaking out of a week-long flat line near $3.50, after the company confirmed it will release topline results from its Phase 2a trial of its lead brain cancer drug tomorrow and host an investor call at 8:30 a.m. Eastern. NeOnc Bets Its Entire Future on Tomorrow's Brain Cancer Data — Is a $3.75 Stock About to Soar or Collapse?
Shares of NeOnc Technologies Holdings (NTHI) surged 7.1% to $3.75 on Monday, snapping a week of flat trading near $3.50, after the company confirmed it will unveil results from its most important clinical trial to date at 8:30 a.m. Eastern on August 12. For a tiny biotech with virtually no revenue and a dwindling cash pile, tomorrow's data readout is as close to an all-or-nothing moment as it gets.
The Drug Being Tested Bypasses the Brain's Natural Shield. The trial evaluated an intranasal spray — the company's lead drug, a purified form of perillyl alcohol — in patients with recurring, hard-to-treat brain tumors carrying a specific genetic mutation (IDH1-mutant high-grade glioma).
In earlier observations, the drug was associated with tumor remission in roughly 24% of recurrent glioblastoma patients, and it is designed for direct nose-to-brain delivery to bypass the blood-brain barrier. That's meaningful because most drugs simply cannot reach the brain in effective doses. The drug has already earned FDA Fast Track, Orphan Drug, and Rare Pediatric Disease designations — special labels that can speed up regulatory reviews.
The Company Is Running on Fumes Financially. As of March 31, NeOnc had just $138,601 in cash, which combined with financing proceeds and a credit line, was expected to fund operations only into September 2026.
Revenue in 2025 was a negligible $39,990, with losses of $62 million — mostly non-cash charges, but the underlying cash burn rate was still roughly $10 million annually. Positive data tomorrow could unlock new fundraising or a partnership; a miss could leave the company in dire straits.
Strong Data Could Open a Fast Lane to Approval — and Acquirer Interest. NeOnc believes positive results may support Breakthrough Therapy designation, expand existing Fast Track benefits, and enhance development under its Orphan Drug status.
The broader glioblastoma treatment market is estimated at $3.24 billion in 2026, growing to $4.65 billion by 2031. Even a niche slice of that market dwarfs NeOnc's current valuation.
The CEO Has Been Buying With His Own Money. SEC filings show CEO Amir Heshmatpour has invested more than $500,000 through open-market purchases, with insider buying approaching $1 million over the past year. That personal conviction is notable, but it doesn't guarantee clinical success. BTIG initiated coverage with a Buy rating and a $15 price target — four times the current price — but that bet rides entirely on tomorrow morning's numbers.